Abstract
Microsatellite instability (MSI) is caused by mutations in the DNA mismatch repair genes and has been shown to predict response to checkpoint inhibitors (CPIs). Both FDA & EMA have approved CPIs in MSI-High (MSI-H) colorectal cancer (CRC). The aim of this study was to understand MSI testing practices for CRC patients, among physicians in Europe and Asia.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
